|
BioScreening - organic compounds for screening
News: Cancer ResearchInvitrogen Scientists Link microRNA Sequences to Cancer Using RNA Samples from BioServe - Carlsbad, Calif., and Beltsville, Md., May 7, 2008 – In research demonstrating that RNA previously thought to have no biological relevance may be of use for therapeutic and diagnostic targets, Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, and BioServe, the leading provider of clinically annotated tissue samples [...]
Validated biomarkers will drive personalized medicine - Biomarkers will be accepted as predicted tools, but their clinical usefulness needs to be understood
first, according to personalized medicine expert.
Coordinating personalized medicine on an international level, Dr Edward Abrahams, Executive
Director of the Personalized Medicine Coalition believes that biomarkers will eventually impact all
disease areas.
“When they were validated, and when it can be understood how clinically useful [...]
Norwich company joins cancer fight - A new company based on the Norwich Research Park has joined the fight against MRSA and cancer.
Researchers at the John Innes Centre near Norwich have launched a new company, Inspiralis, based around their expertise in ‘DNA topoisomerases’.
These are a group of enzymes that help DNA molecules to unravel and wind up properly and not to [...]
DNA with a twist: New company to search for cancer drugs and antibiotics - A new company has joined the fight against MRSA and cancer. Researchers at the John Innes Centre (Norwich) have launched a new company, Inspiralis Ltd, based around their expertise in DNA topoisomerases – a group of enzymes that help DNA molecules to unravel and wind up properly and not to become tangled during replication.
“DNA becomes [...]
New drug target leaves lung cancer cells alone, lonely and dying - It seems even tumour cells can get lonely; scientists have discovered that by cutting off a key gene, lung cancer tumour cells are left ‘homeless’ and they can’t survive on their own.
The gene in question is called 14-3-3zeta and it can now be considered a potential target for selective anticancer drugs, according to Professor Haian [...]
Michael J. Fox Foundation Awards $4.4 Million for Development of New Class of Parkinson’s Therapy - NEW YORK, Dec. 18 /PRNewswire-USNewswire/ — The Michael J. Fox Foundation has awarded $4.4 million to jump-start the development of a new class of symptomatic Parkinson’s disease drugs targeting glutamate receptor mGluR4. The funding was awarded to a multidisciplinary team of researchers led by Jeffrey Conn, PhD, of Vanderbilt University under the Foundation’s LEAPS (Linked [...]
Profiling of Tumor Tissue Slices is Awarded Prize - Novel drug screening tool based on the Bionas® 2500 analyzing system wins silver medal in European business plan contest
Rostock, Germany, November 26, 2007 / b3c newswire / - Bionas GmbH, a specialist for in vitro profiling the metabolic activity of cells, announced that Prof. Pedro Mestres of the Saarland University (Homburg/Saar, Germany) has been awarded [...]
Gossypol Biological Properties - Gossypol:
is a polyphenolic aldehyde that permeates cells and acts as an inhibitor for several dehydrogenase enzymes.
is antimalarial being the selective inhibitor of Plasmodium falciparum (pfLDH over hLDHs), an essential enzyme for energy generation within malarial parasite.
posesses proapoptotic properties, probably due to the regulation of the Bax and Bcl2.
reversibly inhibits Calcineurin and binds to calmodulin.
inhibits replication [...]
Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog - NEWARK, Del., Oct. 2 /PRNewswire-FirstCall/ — Strategic Diagnostics Inc. — today announced the launch of a new internet based catalog of antibody reagents in support of oncology-based research and discovery. These high-quality reagents have all been manufactured utilizing SDI’s proprietary Genomic Antibody Technology(TM) and will carry the SEQer(TM) brand. The catalog is available at http://antibodies.sdix.com [...]
BioServe and Phenomenome Discoveries Develop Novel Diagnostic Test for Colorectal Cancer - Laurel, MD and Saskatoon, SK, Canada, August 6, 2007 – BioServe and Phenomenome Discoveries Inc. (“PDI”) today announced that they have developed a novel serum-based diagnostic test for the identification of colorectal cancer (CRC), and pre-cancerous states conducive to the development of CRC. Colorectal cancer comprises a tenth of the global [...]
Colorectal cancer research surges at Vanderbilt-Ingram Cancer Center - The Vanderbilt-Ingram Cancer Center has landed another round of support for its Specialized Program of Research Excellence (SPORE) in gastrointestinal cancer, one of only five such programs in the country. The National Cancer Institute will provide $11.8 million over the next five years to forward Vanderbilt-Ingram’s innovative colorectal cancer research.
“We received the top score in [...]
BioServe Names Kevin Krenitsky as Chief Executive Officer - Beltsville, MD, May 7, 2007 – BioServe today strengthened its senior management team with the appointment of Kevin Krenitsky, M.D. as Chief Executive Officer. Krenitsky is a highly respected 15-year veteran of the life sciences industry, bringing a wealth of experience in building and managing global biotechnology operations.
“Kevin’s impressive range of experience in diagnostics, pre-clinical [...]
Canadian Cancer Society invests nearly $5-million in local researchers - VANCOUVER, May 2 /CNW/ - The Canadian Cancer Society has awarded more
than $4.8-million to nine cancer research projects in B.C.
The Society’s total research investment across Canada in 2007-08 is over
$47-million and includes 78 new grants. More than 500 research teams
coast-to-coast are currently receiving funds from the Canadian Cancer Society.
“Advances in research over the past few [...]
EpiCept Corporation to Present at the 2007 BIO International Convention - TARRYTOWN, N.Y., May 04, 2007 /PRNewswire-FirstCall/ — EpiCept Corporation today announced that the Company’s management will be making three presentations at the 2007 BIO International Convention, taking place May 6 through May 9, 2007 at the Boston Convention and Exhibition Center, Boston, MA.
Jack Talley, President and CEO, will participate in a Breakout Session entitled, “Creative [...]
Sensitive and Specific Biomarker for Early Detection of Prostate Cancer Identified - Newswise — Scientists at a Maryland-based pharmaceutical company have preliminary evidence showing that a protein in the blood may prove to be a biomarker that is more sensitive and specific than current methods of early detection for prostate cancer.
If they’re right, the protein – an enzyme called human aspartyl (asparaginyl) beta-hydroxylase, or HAAH – could [...]
Improved In Vitro Genotoxicity Testing to Reduce Animal Testing - n conjunction with the University of Manchester, Gentronix has been granted a research award of £133,024 by the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs).
One of nine awards made by NC3Rs in 2006, the funding will be used to develop a novel genotoxicity assay in a human liver cell [...]
Data Presented on Anti-Cancer Compound ON 01910.Na at American Society of Clinical Oncology (ASCO) Conference; ON 01910.Na active in inducing regression of pre-established intracranial tumors in a model system - ATLANTA–(BUSINESS WIRE)–Jun 5, 2006 - Dr. Jasti Rao, an investigator at the University of Illinois, in collaboration with Onconova Therapeutics, Inc., presented data yesterday highlighting the activity of therapeutic candidate ON 01910.Na in brain cancer or glioblastoma. The data were presented at the American Society for Clinical Oncology (ASCO) annual meeting being held in Atlanta.
“ON [...]
Proteins linked to cancer prevention in humans affect aging in worms - Discovery opens a new avenue of inquiry into aging as a risk factor for cancer
Novato, CA – Proteins which prevent cancer in humans by ensuring that cells don’t divide if they have chromosomal damage have been shown to determine lifespan in the nematode worm C. elegans. A Buck Institute study, appearing in the June 2nd [...]
The next generation of interferons needs improvement in efficacy and safety - The interferon alpha market is smaller than the interferon beta market, but is characterized by far more products and R&D projects. Conversion of the interferon alpha market to pegylated products explains why new R&D is focused on interferon alpha variants or other subtypes with improved pharmacodynamic and safety properties.
BARCELONA, Spain | May 18, [...]
New Target in the War on Cancer Ready to Download to Your Computer - In the news release, New Target in the War on Cancer Ready to Download to Your Computer, issued earlier today by The Rothberg Institute for Childhood Diseases over PR Newswire, we are advised by the company that the subhead, should read “‘We’re excited to have a target that anyone can download to their personal computer [...]
Sponsored Links
|
|
